Oncology Institute (NASDAQ:STLN) Stock Sale Reported by Sen. Richard Blumenthal

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 23rd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Price Performance

Shares of STLN stock opened at $6.64 on Thursday. The stock has a fifty day moving average price of $6.47. The stock has a market cap of $656.29 million, a price-to-earnings ratio of -22.13 and a beta of 0.39. Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $7.13.

Oncology Institute (NASDAQ:STLN) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $161.28 million during the quarter, compared to analysts’ expectations of $152.80 million. Equities analysts predict that Oncology Institute, Inc. will post -0.21 earnings per share for the current year.

Institutional Trading of Oncology Institute

Institutional investors have recently made changes to their positions in the company. State Street Corp purchased a new position in Oncology Institute in the second quarter worth approximately $8,432,000. The Manufacturers Life Insurance Company acquired a new stake in Oncology Institute during the second quarter worth $111,000. WINTON GROUP Ltd purchased a new stake in Oncology Institute in the second quarter valued at $102,000. Engineers Gate Manager LP purchased a new stake in Oncology Institute in the second quarter valued at $67,000. Finally, Squarepoint Ops LLC purchased a new stake in Oncology Institute in the second quarter valued at $396,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Insider Buying and Selling at Oncology Institute

In other Oncology Institute news, major shareholder Jorey Chernett acquired 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, with a total value of $78,480.00. Following the transaction, the insider owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the sale, the director directly owned 411,976 shares of the company’s stock, valued at $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Lake Street Capital initiated coverage on Oncology Institute in a research report on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective on the stock. BTIG Research raised their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Weiss Ratings started coverage on shares of Oncology Institute in a report on Thursday, August 6th. They set a “sell (d-)” rating for the company. Finally, Needham & Company LLC lifted their target price on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.